PL368539A1 - Kombinacja inhibitora cyklooksygenazy-2 z inhibitorem deacetylazy histonu - Google Patents

Kombinacja inhibitora cyklooksygenazy-2 z inhibitorem deacetylazy histonu

Info

Publication number
PL368539A1
PL368539A1 PL02368539A PL36853902A PL368539A1 PL 368539 A1 PL368539 A1 PL 368539A1 PL 02368539 A PL02368539 A PL 02368539A PL 36853902 A PL36853902 A PL 36853902A PL 368539 A1 PL368539 A1 PL 368539A1
Authority
PL
Poland
Prior art keywords
inhibitor
combination
cyclooxygenase
histone deacetylase
relates
Prior art date
Application number
PL02368539A
Other languages
English (en)
Other versions
PL205853B1 (pl
Inventor
Ying-Nan Pan Chen
Peter Lassota
Alexander Wallace Wood
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL368539A1 publication Critical patent/PL368539A1/pl
Publication of PL205853B1 publication Critical patent/PL205853B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
PL368539A 2001-11-06 2002-11-05 Kombinacja zawierająca inhibitor COX-2 oraz inhibitor deacetylazy histonów, kompozycja farmaceutyczna zawierająca inhibitor COX-2 oraz inhibitor deacetylazy histonów, zastosowanie tej kombinacji oraz opakowanie handlowe lub produkt handlowy obejmujący inhibitor COX -2 oraz inhibitor deacetylazy histonów PL205853B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33301601P 2001-11-06 2001-11-06
US41931402P 2002-10-17 2002-10-17

Publications (2)

Publication Number Publication Date
PL368539A1 true PL368539A1 (pl) 2005-04-04
PL205853B1 PL205853B1 (pl) 2010-06-30

Family

ID=26988512

Family Applications (1)

Application Number Title Priority Date Filing Date
PL368539A PL205853B1 (pl) 2001-11-06 2002-11-05 Kombinacja zawierająca inhibitor COX-2 oraz inhibitor deacetylazy histonów, kompozycja farmaceutyczna zawierająca inhibitor COX-2 oraz inhibitor deacetylazy histonów, zastosowanie tej kombinacji oraz opakowanie handlowe lub produkt handlowy obejmujący inhibitor COX -2 oraz inhibitor deacetylazy histonów

Country Status (22)

Country Link
US (3) US7402603B2 (pl)
EP (1) EP1443967B1 (pl)
JP (1) JP4413614B2 (pl)
KR (1) KR100937064B1 (pl)
CN (1) CN100457183C (pl)
AT (1) ATE352319T1 (pl)
AU (1) AU2002351844B2 (pl)
BR (1) BR0213932A (pl)
CA (1) CA2461373A1 (pl)
CY (1) CY1106508T1 (pl)
DE (1) DE60217895T2 (pl)
DK (1) DK1443967T3 (pl)
ES (1) ES2280597T3 (pl)
HU (1) HUP0402370A3 (pl)
IL (2) IL160970A0 (pl)
MX (1) MXPA04004312A (pl)
NO (1) NO20042148L (pl)
NZ (1) NZ544689A (pl)
PL (1) PL205853B1 (pl)
PT (1) PT1443967E (pl)
RU (1) RU2311200C2 (pl)
WO (1) WO2003039599A1 (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
KR20050122210A (ko) * 2003-03-17 2005-12-28 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
AR043850A1 (es) * 2003-04-17 2005-08-17 Bayer Pharmaceuticals Corp Acidos hidroxamicos utiles en el tratamiento de trastornos hiperproliferativos
MXPA05012464A (es) * 2003-05-21 2006-01-30 Novartis Ag Combinacion de inhibidores de deacetilasa de histona con agentes quimioterapeuticos.
EP1491188A1 (en) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topical use of valproic acid for the prevention or treatment of skin disorders
WO2005066151A2 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2005065681A1 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
RU2391340C2 (ru) * 2004-08-11 2010-06-10 Киорин Фармасьютикал Ко., Лтд. Новое циклическое производное аминобензойной кислоты
JP2008524246A (ja) 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
US7786330B2 (en) 2005-02-28 2010-08-31 Asahi Glass Company, Limited Process for producing 1,2-dialkoxy-3-fluorobenzene
WO2006122319A2 (en) * 2005-05-11 2006-11-16 Takeda San Diego, Inc. Histone deacetylase inhibitors
ZA200800901B (en) 2005-07-14 2010-05-26 Takeda San Diego Inc Histone deacetylase inhibitors
EP1743654A1 (en) * 2005-07-15 2007-01-17 TopoTarget Germany AG Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
WO2007016136A2 (en) * 2005-07-28 2007-02-08 Nitromed, Inc. Organic nitric oxide enhancing salts of cyclooxygenase-2 selective inhibitors, compositons and methods of use
WO2007084390A2 (en) * 2006-01-13 2007-07-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
RU2008151724A (ru) * 2006-06-12 2010-07-20 Новартис АГ (CH) Способ получения солей n-гидрокси-3-[4-[[[2-(2-метил-1н-индол-3-ил)этил]амино]метил]фенил]-2е-2-пропенамида
HRP20130798T1 (en) 2006-06-12 2013-09-30 Novartis Ag Process for making n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide and starting materials therefor
KR20090015968A (ko) 2006-06-12 2009-02-12 노파르티스 아게 Ｎ-히드록시-3-[4-[[[2-(2-메틸-1ｈ-인돌-3-일)에틸]아미노]메틸]페닐]-2ｅ-2-프로펜아미드의 동질이상체
WO2008002634A1 (en) * 2006-06-28 2008-01-03 Novartis Ag Use of hdac inhibitors for the treatment of lymphomas
JPWO2008023438A1 (ja) 2006-08-25 2010-01-07 旭硝子株式会社 １，２−ジアルコキシ−３−フルオロベンゼンの製造方法
BRPI0806365B8 (pt) 2007-02-06 2021-05-25 Lixte Biotechnology Holdings Inc composto, uso do composto, composição farmacêutica e uso da composição farmacêutica
EP2491923A3 (en) * 2007-02-15 2012-12-26 Novartis AG Combinations of therapeutic agents for treating cancer
WO2009045440A1 (en) 2007-10-01 2009-04-09 Lixte Biotechnology Holdings, Inc. Hdac inhibitors
US8058268B2 (en) 2008-08-01 2011-11-15 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
US8227473B2 (en) 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
KR20140144696A (ko) * 2012-04-16 2014-12-19 도아 에이요 가부시키가이샤 ２환성 화합물
CA2909160C (en) 2013-04-09 2021-05-25 Lixte Biotechnology, Inc. Formulations of oxabicycloheptanes and oxabicycloheptenes
EP3932914A1 (en) 2015-03-13 2022-01-05 Valo Health, Inc. Alpha-cinnamide compounds and compositions as hdac8 inhibitors
WO2018107004A1 (en) 2016-12-08 2018-06-14 Lixte Biotechnology, Inc. Oxabicycloheptanes for modulation of immune response
CN115108926B (zh) * 2022-04-02 2023-06-20 上海工程技术大学 一种用于制备厄达替尼的中间体化合物及制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)

Also Published As

Publication number Publication date
ES2280597T3 (es) 2007-09-16
EP1443967A1 (en) 2004-08-11
CN100457183C (zh) 2009-02-04
ATE352319T1 (de) 2007-02-15
HUP0402370A3 (en) 2008-04-28
KR100937064B1 (ko) 2010-01-15
CN1578674A (zh) 2005-02-09
RU2004117170A (ru) 2005-04-20
NO20042148L (no) 2004-08-04
NZ544689A (en) 2007-08-31
RU2311200C2 (ru) 2007-11-27
HUP0402370A2 (hu) 2005-02-28
IL160970A (en) 2010-06-30
US20050032899A1 (en) 2005-02-10
JP2005510517A (ja) 2005-04-21
KR20050043744A (ko) 2005-05-11
EP1443967B1 (en) 2007-01-24
IL160970A0 (en) 2004-08-31
JP4413614B2 (ja) 2010-02-10
PL205853B1 (pl) 2010-06-30
MXPA04004312A (es) 2005-05-16
DK1443967T3 (da) 2007-04-16
PT1443967E (pt) 2007-04-30
AU2002351844B2 (en) 2006-12-21
DE60217895D1 (en) 2007-03-15
US20090192211A1 (en) 2009-07-30
WO2003039599A1 (en) 2003-05-15
CY1106508T1 (el) 2012-01-25
CA2461373A1 (en) 2003-05-15
US20080227845A1 (en) 2008-09-18
BR0213932A (pt) 2004-08-31
DE60217895T2 (de) 2007-07-05
US7402603B2 (en) 2008-07-22

Similar Documents

Publication Publication Date Title
DE60217895D1 (en) Kombination cyclooxygenase-2 inhibitor/ histone deacetylase inhibitor
MXPA05012464A (es) Combinacion de inhibidores de deacetilasa de histona con agentes quimioterapeuticos.
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
JO2434B1 (en) New retinoids to treat emphysema
EA200401471A1 (ru) Применение ингибиторов сетр и возможных ингибиторов hmg coa и/или антигипертензивных агентов
WO2008114262A3 (en) Oligoribonucleotide inhibitors of nrf2 and methods of use thereof for treatment of cancer
EP1461313A4 (en) INHIBITORS OF HUMAN ADAM-10
BR9611897A (pt) Benzofurano carboxamidas e sulfonamidas
AU2003205768A1 (en) Methods and compositions for treating hyperproliferative conditions
MY148893A (en) Combination of an hdac inhibitor and an antimetabolite
WO2007002836A3 (en) Methods and compositions for the prevention and treatment of kidney disease
ES2124983T3 (es) Utilizacion de un antagonista de substancia p para el tratamiento de las manchas rojas cutaneas de origen neurogeno.
WO2007128588A3 (de) Glutadon
AU2003250190A1 (en) Combination of an aromatase inhibitor with a bisphosphonate
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
AU2003242512A1 (en) Use of compounds capable of inhibiting the proteolytic processing of semaphorins for prevention, treatment, diagnosis and prognosis of an invasive disease
BRPI0507482A (pt) combinação de (a) um inibidor de dna topoisomerase e (b) um inibidor de iap
PL370361A1 (pl) Retynoidowi agoniści I typu alkilomocznika
IL125441A0 (en) Novel diphenyl stilbenes and pharmaceutical compositions thereof for treatment of cox-2 mediated diseases
DE602004019500D1 (en) 4-substituirte-5-cyano-1h-pyrimidin-6-(th)iones als als gsk-3-hemmer
WO2002096870A3 (en) Sponge-derived terpenoids and methods of use
PL367707A1 (pl) Kompozycja farmaceutyczna stosowana w leczeniu nowotworów złośliwych zawierająca kombinację bisfosfonianu, inhibitora COX-2 i taksolu
PL370459A1 (pl) Retynoidowi agoniści II typu podstawionego mocznika
JP2005506371A5 (pl)
WO2005044301A3 (en) Use of specific histones for the treatment of parasitic diseases

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20111105